130 related articles for article (PubMed ID: 15948124)
1. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma.
Grobholz R; Griebe M; Sauer CG; Michel MS; Trojan L; Bleyl U
Hum Pathol; 2005 May; 36(5):562-70. PubMed ID: 15948124
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades.
Weichert W; Schmidt M; Gekeler V; Denkert C; Stephan C; Jung K; Loening S; Dietel M; Kristiansen G
Prostate; 2004 Aug; 60(3):240-5. PubMed ID: 15176053
[TBL] [Abstract][Full Text] [Related]
3. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
6. [Relevance of the neuroendocrine differentiation in prostatic carcinoma].
Sauer CG; Trojan L; Grobholz R
Pathologe; 2005 Nov; 26(6):444-52. PubMed ID: 16133158
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
9. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
[TBL] [Abstract][Full Text] [Related]
12. Release of macrophage migration inhibitory factor by neuroendocrine-differentiated LNCaP cells sustains the proliferation and survival of prostate cancer cells.
Tawadros T; Alonso F; Jichlinski P; Clarke N; Calandra T; Haefliger JA; Roger T
Endocr Relat Cancer; 2013 Feb; 20(1):137-49. PubMed ID: 23207293
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the prostate: an immunoelectron microscopic study.
Hirano D; Jike T; Okada Y; Minei S; Sugimoto S; Yamaguchi K; Yoshikawa T; Hachiya T; Yoshida T; Takimoto Y
Ultrastruct Pathol; 2005; 29(5):367-75. PubMed ID: 16257863
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
15. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
16. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.
Grobholz R; Bohrer MH; Siegsmund M; Jünemann KP; Bleyl U; Woenckhaus M
Pathol Res Pract; 2000; 196(5):277-84. PubMed ID: 10834383
[TBL] [Abstract][Full Text] [Related]
17. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
18. [Immunohistochemical and morphometric studies on neuroendocrine differentiation of prostate carcinomas].
Bohrer MH; Schmoll J
Verh Dtsch Ges Pathol; 1993; 77():107-10. PubMed ID: 7511265
[TBL] [Abstract][Full Text] [Related]
19. Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index.
Horn LC; Hentschel B; Bilek K; Richter CE; Einenkel J; Leo C
Ann Diagn Pathol; 2006 Jun; 10(3):140-3. PubMed ID: 16730307
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine differentiation in the progression of prostate cancer.
Komiya A; Suzuki H; Imamoto T; Kamiya N; Nihei N; Naya Y; Ichikawa T; Fuse H
Int J Urol; 2009 Jan; 16(1):37-44. PubMed ID: 19120524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
